Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY

— Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) — — RSV neutralizing antibodies for Clover’s non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted AREXVY in older adults,…